Clarivate provides data, analytics, and workflow software to researchers, academic institutions, corporations, law firms, and life sciences companies. Its products help customers discover scientific knowledge, manage intellectual property, and navigate drug development decisions. The unifying thread across Clarivate's businesses is proprietary, curated data — citation networks, patent databases, pharmaceutical pipelines — which customers use as a trusted foundation for research and decision-making. Clarivate operates through three segments: Academia & Government (A&G), Intellectual Property (IP), and Life Sciences & Healthcare (LS&H). A&G is built around Web of Science (a citation index used in 75% of national research assessments globally), ProQuest content solutions for academic libraries, and library management software such as Alma. IP serves corporations and law firms through patent renewal services, the Derwent patent intelligence platform, trademark services, and IP management software. LS&H serves pharma and biotech customers through Cortellis (drug development intelligence) and DRG Commercial Analytics. Clarivate sells primarily through annual subscriptions and long-term enterprise agreements, with renewal rates consistently above 90%. Revenue also includes re-occurring patent and trademark renewal filings, and a declining tail of transactional revenue that Clarivate is deliberately winding down to improve margins and shift recurring revenue mix toward 87%+. Clarivate serves more than 45,000 customers globally and is embedding AI across its flagship products, including AI-powered patent search and a conversational regulatory assistant in Cortellis.